Search This Blog

Monday, October 12, 2026

JPMorgan upgrades Biogen to Overweight, raises price target to $300

 

 on stronger pipeline catalyst and growth outlook

  • Upgrade from Neutral reflects an increasingly compelling pipeline catalyst outlook, according to JPMorgan
  • JPMorgan cites improved long-term growth prospects as key support for its new $300 price target
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)